NCT00727831View on ClinicalTrials.gov

Methotrexate, Glucarpidase, and Leucovorin in Treating Patients With Newly Diagnosed Primary Central Nervous System Lymphoma

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

4

Participants

Timeline

Start Date

July 31, 2008

Primary Completion Date

July 31, 2011

Study Completion Date

July 31, 2011

Conditions
Chemotherapeutic Agent ToxicityLymphomaMucositisNeurotoxicity
Interventions
DRUG

glucarpidase

DRUG

leucovorin calcium

DRUG

methotrexate

OTHER

laboratory biomarker analysis

PROCEDURE

quality-of-life assessment

RADIATION

radiation therapy

Trial Locations (2)

LS1 3EX

Leeds General Infirmary, Leeds

TQ2 7AA

Torbay Hospital, Torquay

Sponsors

Collaborators (1)

Cancer Research UK
All Listed Sponsors
collaborator

Cancer Research UK

OTHER

lead

University College, London

OTHER

NCT00727831 - Methotrexate, Glucarpidase, and Leucovorin in Treating Patients With Newly Diagnosed Primary Central Nervous System Lymphoma | Biotech Hunter | Biotech Hunter